Actavis Inc has entered into a partnership with QRxPharma to commercialise MoxDuo IR in the US.

Under the terms of a letter of intent, Actavis has exclusive rights to launch and market MoxDuo IR, a patented fixed-dose combination of morphine and oxycodone in a 3:2 ratio.

The product will launch in the US is expected in the third quarter of 2012, with pre-launch preparations set to begin immediately.

Actavis CEO Claudio Albrecht said that the company is serious in its quest to be ahead of the changing generic pharmaceutical industry.

"In the future, there will not be such a clear difference between innovator and generic companies. The lines between the two models are blurring. The generics business as we know it today will be gone within the next ten years," Albrecht said.

This transaction builds on Actavis’s success with the currently marketed Kadian (extended-release morphine sulphate) capsules, and a broad array of generic scheduled narcotics offerings.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.